J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (40)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chow, S. L.
Right arrow Articles by Lopez-Candales, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chow, S. L.
Right arrow Articles by Lopez-Candales, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PHARMACOKINETICS AND PHARMACODYNAMICS

Correlation of Antifactor Xa Concentrations with Renal Function in Patients on Enoxaparin

Sheryl L. Chow, PharmD, Kimberly Zammit, PharmD, Kathleen West, PharmD, MaryAnne Dannenhoffer, PharmD and Angel Lopez-Candales, MD

From the University at Buffalo, State University of New York, Kaleida Health Systems, Buffalo, New York.

Enoxaparin is a low molecular weight heparin (LMWH) that has been shown to be effective in deep vein thrombosis, pulmonary embolism, and unstable angina. Because renal function plays an important role in the clearance of LMWH, the authors sought to investigate the effect of renal function on enoxaparin. This prospective multiple-dose study evaluated 18 patients with varying degrees of renal function initiated on enoxaparin 1 mg/kg subcutaneously every 12 hours. Peak blood levels of anti-Xa concentrations were obtained 4 ± 0.5 hours postdose after receiving at least three doses of enoxaparin. The median antifactor Xa levels were higher in patients with creatinine clearance (CLCr) <= 30 mL/min compared to CLCr >= 31 mL/min (1.34 IU/mL vs. 0.91 IU/mL, respectively, p < 0.05). A linear correlation was established between creatinine clearance and anti-Xa concentrations (p< 0.0005). On the basis of the data, the authors believe that a dose adjustment is necessary in patients receiving repeated doses of enoxaparin with CLCr <= 30 mL/min.

Key Words: Low molecular weight heparin • enoxaparin • antifactor Xa • renal function

Address for reprints: Sheryl L. Chow, Adjunct Clinical Assistant Professor, University at Buffalo, School of Pharmacy, Kaleida Health Systems, Millard Fillmore Hospital, Department of Pharmacy, 3 Gates Circle, Buffalo, NY 14209.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
E. A Nutescu, S. A Spinler, A. Wittkowsky, and W. E Dager
Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
Ann. Pharmacother., June 1, 2009; 43(6): 1064 - 1083.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. Hirsh, K. A. Bauer, M. B. Donati, M. Gould, M. M. Samama, and J. I. Weitz
Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 141S - 159S.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
B. L. Lobo
Use of newer anticoagulants in patients with chronic kidney disease
Am. J. Health Syst. Pharm., October 1, 2007; 64(19): 2017 - 2026.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
T. S. Dharmarajan and A. Sohagia
Low-molecular-weight heparin and bleeding: how do we lower risk but maintain benefit?
Ann Intern Med, November 21, 2006; 145(10): 789 - 790.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
W. Lim, F. Dentali, J. W. Eikelboom, and M. A. Crowther
Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency
Ann Intern Med, May 2, 2006; 144(9): 673 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
N. L. K. Tam, C. Pac-Soo, and P. M. Pretorius
Epidural haematoma after a combined spinal-epidural anaesthetic in a patient treated with clopidogrel and dalteparin
Br. J. Anaesth., February 1, 2006; 96(2): 262 - 265.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
E. Anton
A Correct Evaluation of Renal Function Could Decrease Bleeding Risk in Anticoagulated Elderly Patients
Arch Intern Med, February 14, 2005; 165(3): 349 - 350.
[Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
G. F. Pineo and R. D. Hull
Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly
Clinical and Applied Thrombosis/Hemostasis, January 1, 2005; 11(1): 15 - 23.
[Abstract] [PDF]

Home page
 ChestHome page
J. Hirsh and R. Raschke
Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 188S - 203S.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. C Gosselin, J. H King, K. A Janatpour, W. E Dager, E. C Larkin, and J. T Owings
Variability of Plasma Anti-Xa Activities with Different Lots of Enoxaparin
Ann. Pharmacother., April 1, 2004; 38(4): 563 - 568.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Clinical Pharmacology